Table 2.
Conversion characteristics and follow-up
| Variables | Belatacept |
|---|---|
| Patients, n | 12 |
| Post-transplantation switch onset, months, median (IQR) | 10 (2–25) |
| Early (<3 months), n (%) | 3 (25) |
| Late (>3 months), n (%) | 9 (75) |
| Cause of switch, n (%) | |
| Vascular | 3 (25) |
| CNI toxicity | 5 (42) |
| Graft dysfunction | 4 (33) |
| eGFR, median (IQR), mL/min/1.73 m2 | 13 (9–19) |
| Proteinuria/creatininuria ratio, median (IQR) | 37 (12–57) |
| Follow-up | |
| 3 months, recipients, n | 11 |
| eGFR, median (IQR), mL/min/1.73 m2 | 18 (14–22) |
| Proteinuria/creatininuria ratio, median (IQR) | 14 (6–35) |
| Acute rejection, n (%) | 1 (8) |
| CD4, median (IQR), mm3 | 213 (90–292) |
| CD8, median (IQR), mm3 | 319 (196–319) |
| HIV reactivation, n (%) | 1 (8) |
| Patient death, n (%) | 0 (0) |
| Kidney allograft loss, n (%) | 1 (8) |
| OI, n (%) | 3 (25) |
| Belatacept stopped, n (%) | 1 (8) |
| 12 months, recipients, n | 9 |
| eGFR, median (IQR), mL/min/1.73 m2 | 18 (15–27) |
| Proteinuria/creatininuria ratio, median (IQR) | 30 (15–63) |
| Acute rejection, n (%) | 1 (9) |
| CD4, median (IQR), mm3 | 318 (150–608) |
| CD8 (mm3), median (IQR) | 567 (299–1036) |
| HIV reactivation, n (%) | 2 (17) |
| Patient death, n (%) | 1 (8) |
| Kidney allograft loss, n (%) | 1 (8) |
| OI, n (%) | 2 (17) |
| Belatacept stopped, n (%) | 3 (25) |
| End of follow-up | |
| eGFR, median (IQR), mL/min/1.73 m2 | 23 (15–27) |
| Proteinuria/creatininuria ratio, median (IQR) | 46 (8–68) |
| Acute rejection, n (%) | 2 (17) |
| CD4, median (IQR), mm3 | 215 (148–380) |
| CD8, median (IQR), mm3 | 483 (282–887) |
| HIV reactivation, n (%) | 2 (17) |
| Patient death, n (%) | 2 (17) |
| Kidney allograft loss, n (%) | 2 (17) |
| OI, n (%) | 3 (25) |
| Belatacept stopped, n (%) | 5 (42) |